Last reviewed · How we verify
HAV vaccine
HAV vaccine stimulates the immune system to produce antibodies against hepatitis A virus, providing protection against infection.
HAV vaccine stimulates the immune system to produce antibodies against hepatitis A virus, providing protection against infection. Used for Prevention of hepatitis A infection in susceptible populations, Post-exposure prophylaxis for hepatitis A.
At a glance
| Generic name | HAV vaccine |
|---|---|
| Sponsor | International Agency for Research on Cancer |
| Drug class | Inactivated viral vaccine |
| Target | Hepatitis A virus surface antigens |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
The vaccine contains inactivated hepatitis A virus or viral antigens that trigger both humoral (antibody) and cellular immune responses. This leads to the production of anti-HAV antibodies and immunological memory, preventing infection if exposed to wild-type hepatitis A virus. Protection is typically long-lasting, often lifelong after a complete vaccination series.
Approved indications
- Prevention of hepatitis A infection in susceptible populations
- Post-exposure prophylaxis for hepatitis A
Common side effects
- Injection site pain or erythema
- Headache
- Fatigue
- Myalgia
- Low-grade fever
Key clinical trials
- DNA Vaccine Therapy in Treating Patients With Chronic Hepatitis C Virus Infection (PHASE1)
- Longitudinal Tracking of Bone Marrow Plasma Cell Responses to Licensed Human Vaccines (PHASE4)
- A Study to Assess the Experimental Malaria Vaccines R78C and RH5.1 With Matrix-M in Combination With R21/Matrix-M (PHASE2)
- Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age (PHASE3)
- Serosurvey of HAV Immunity and Single-dose Vaccine Immunogenicity Among Patients With Cirrhosis
- Lot-to-lot Consistency Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From 2 Months of Age (PHASE3)
- R21/Matrix-M in African Children Against Clinical Malaria (PHASE3)
- Safety, Efficacy, Immunogenicity Study of GSK Biologicals' HBV Viral Vector and Adjuvanted Proteins Vaccine (GSK3528869A) in Adult Patients With Chronic Hepatitis B Infection (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HAV vaccine CI brief — competitive landscape report
- HAV vaccine updates RSS · CI watch RSS
- International Agency for Research on Cancer portfolio CI